Compared with the corresponding radiolabeled agonist, antagonists of GRPR without internalizing or activating it were able to recognize more binding sites than agonists and had an even better tumor uptake and retention in GRPR positive tumors (Stott Reynolds et al., 2018). The gene discussed is GRPR; the disease is neoplasm.